Alzheimer’s drug Leqembi shows promise as injection
Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient …
Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient …
In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket | Getty …
The Club’s 10 things to watch Friday, July 28 We’re watching the bond market Friday after Thursday’s spike in yields triggered a late-day reversal for equities, ending the Dow Jones …
A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs …
Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson …
Here are the most important news items that investors need to start their trading day: 1. Dow on a tear 2. Bank earnings drive the day 3. Goldman drops recession …
The Food and Drug Administration (FDA) fully approved the Alzheimer’s treatment Leqembi on Thursday, marking a significant expansion in access to the costly drug for older Americans. Medicare announced that …
The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s …
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Monday said it applied for full U.S. Food and …